<DOC>
	<DOCNO>NCT00492401</DOCNO>
	<brief_summary>This phase II trial study well decitabine work treat patient previously untreated acute myeloid leukemia . Drugs use chemotherapy , decitabine , work different way stop growth cancer cell , either kill cell stop divide</brief_summary>
	<brief_title>Decitabine Treating Patients With Previously Untreated Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine rate complete remission ( CR ) patient previously untreated acute myeloid leukemia treat decitabine . SECONDARY OBJECTIVES : I . Determine rate overall survival 1 year patient treat drug . II . Determine overall response rate ( CR , incomplete CR , partial remission ) patient treat drug . III . Correlate biological activity decitabine clinical endpoint maximum concentration plasma decitabine . IV . Correlate intracellular concentration decitabine global DNA methylation , biological endpoint , clinical response . OUTLINE : Patients receive decitabine IV 1 hour day 1-10 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo bone marrow aspiration blood sample collection periodically pharmacological correlative study . Samples analyze gene expression , methylation gene promoter , fetal hemoglobin ( HgF ) , DNMT1 protein expression , maximum concentration plasma decitabine , global DNA methylation . Samples analyze RT-PCR , Bio-COBRA , matrix-assisted laser desorption ionization time-of-flight mass spectrometry , SDS-PAGE ( polyacrylamide gel electrophoresis ) , immunoblotting , LC-MS/MS . After completion study treatment , patient follow least 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Histologically cytologically confirm acute myeloid leukemia ( AML ) meet 1 follow criterion : At least 60 year age candidate refuse standard induction treatment Poor risk cytogenetics AML follow antecedent hematologic disorder Therapyrelated AML Secondary AML No granulocytic sarcoma sole site disease No active CNS disease CNS relapse ECOG performance status 02 Life expectancy &gt; 6 month Total bilirubin &lt; 2.0 mg/dL Creatinine &lt; 2.0 mg/dL AST ALT &lt; 2.5 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No NYHA class III IV congestive heart failure No uncontrolled infection No history allergic reaction attribute compound similar chemical biologic composition decitabine easily manage No uncontrolled illness include , limited , follow : Symptomatic congestive heart failure Unstable angina pectoris Serious cardiac arrhythmia Psychiatric illness social situation would preclude compliance study requirement No active second malignancy involve blood marrow likely progress require therapy next 6 month No prior therapy AML except emergency leukapheresis hydroxyurea leukocytosis No prior azacitidine decitabine No prior cytarabine conventional chemotherapy agent antecedent hematologic disorder Prior myeloid growth factor , recombinant erythropoietin , thalidomide , lenalidomide allow No concurrent palliative radiotherapy No concurrent investigational agent No concurrent direct antileukemia therapy No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>